• Services

    Services

    Inoviem provides a full range of services from drug discovery to clinical development by leveraging its platforms and direct access to human pathological specimens.
    All the platforms and services are label-free with no modification of the original molecules.

    Target & MoA Deconvolution

    Unravel disease relevant Mode of Action (MoA) of your molecule directly on human tissues. 

    Target Validation & Engagement

    Identify and validate targets in your study model or in Human.

    Indication Prioritization

    Thanks to our ex-vivo pharmacology expertise we identify the best disease and patients subgroups.

    Patient Cohort Stratification

    Using patients’ samples and PIMS® technology, we identify those individuals who can benefit best from your compound as soon as the early stage of preclinical studies.

    Lead Compound Selection

    Compounds of interest can be profiled for their drugability based on their mode of action and efficacy.

    Biomarker Discovery

    Translational pharmacology empowers your ability to identify biomarkers and advance clinical developments.

    SPR and Proteomics

    Advanced SPR and proteomics drive precise analysis of biomolecular interactions and protein landscapes.

    Human Biological Samples Provision

    Meticulous collection and biobanking of human samples fuel robust, translational research.

  • Platforms

    Platforms

    Inoviem provides breakthrough protein technologies for each phase of the drug development process.
    One of the major advantages of our label-free technologies used under physiological conditions and in human tissue – NPOT® and PIMS® – is that the test compound retains its original structure, as well as the exact same molecular structure that would be used in therapy

    NPOT®

    Unlocking drug mechanism of action in native biological contexts

    Read more

    LIPS

    Designed to measure drug-target interactions with high accuracy in native environments, including cultured cells and patient tissues.

    Read more

    PIMS®

    Designed to study molecular interactions and predict therapeutic responses in biomedical research

    Read more

    Biomarkers discovery

    Methodology for the proteomic profiling of human individuals in the context of translational evaluation of biomarkers and clinical development of new drug candidates.

    Read more

  • Knowledge centre
  • About us

    About us

    Inoviem Scientific is a Bioanalytical R&D company established in 2011 in Strasburg – France.

    Our mission

    Our mission is clear: to get the right treatment to the right patients within the right therapeutic window.

    Read more

    Our team

    • Management team
    • Scientific board
    • Supervisory board & investors

    Read more

  • Contact us

Author: Alessandro Bona

Inoviem Scientific and DeepLife partner to advance novel target discovery in IBD

  Strasbourg and Paris, France, 26 August 2026 — Inoviem Scientific, a translational pharmacology company specialising in evaluating drug activity and mechanisms directly in human pathological tissue, and DeepLife, a Paris-based techbio company developing AI-powered digital twins of human cells, today announced a strategic collaboration focused on inflammatory bowel disease (IBD). Through the collaboration, DeepLife […]

abc biopply and Inoviem Scientific partner to boost translational accuracy of preclinical modeling

Abc + Inoviem Press Release

  SOLOTHURN, Switzerland  ILLKIRCH-GRAFFENSTADEN, France – 10/10/2025  abc biopply ag, a Swiss biotech company specializing in humanized 3D disease models, and Inoviem Scientific, a French bioanalytical R&D company, have entered a strategic collaboration to develop and commercialize a new preclinical service for the pharmaceutical and biotech industries. This joint effort will create a highly predictive, patient-relevant […]

Need Help